Prurigo nodularis

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Retrieved on: 
Wednesday, November 1, 2023

NEW HAVEN, Conn., Nov. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, November 9, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2023.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 5615817.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients

Retrieved on: 
Thursday, October 26, 2023

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.

Key Points: 
  • Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.
  • Nemolizumab was well tolerated, and its safety profile was consistent with phase II trial results.1
    This press release features multimedia.
  • Results from the phase III OLYMPIA 2 trial will be submitted to selected health authorities around the world.
  • To learn more about prurigo nodularis, watch this video from the New England Journal of Medicine.

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Retrieved on: 
Wednesday, October 11, 2023

Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.

Key Points: 
  • Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively.
  • The late-breaking data were presented today at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin.
  • View the full release here: https://www.businesswire.com/news/home/20231011848851/en/
    “While atopic dermatitis and prurigo nodularis are distinct diseases, their commonality lies in the severe, persistent itch, which leads to poor quality sleep and negatively impacts mental health.
  • Statistically significant results at week 16 and earlier time points also show nemolizumab’s rapid onset of action on itch and sleep disturbance.

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Retrieved on: 
Friday, October 13, 2023

NEW HAVEN, Conn., Oct. 13, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications and prurigo nodularis, today announced the 52-week results from its phase 2b/3 PRISM open-label extension (OLE) study of Haduvio for the treatment of prurigo nodularis. The data was presented by Professor Elke Weisshaar on October 13th at the European Academy of Dermatology & Venereology (EADV) Congress 2023 in Berlin, Germany. The slides from the presentation will be available for 30 days on the Company's website.  

Key Points: 
  • The slides from the presentation will be available for 30 days on the Company's website .
  • "The long-term data also supports the continued effectiveness of Haduvio in reducing itch over 52 weeks for the participants who remained in the study.
  • We are preparing for an end of phase 2 meeting with the FDA to discuss next steps in development for this program."
  • The phase 2b/3 PRISM (Pruritus Relief through Itch-Scratch Modulation) trial was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nalbuphine ER in prurigo nodularis.

EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology

Retrieved on: 
Wednesday, October 4, 2023

Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in Berlin, October 11-14, 2023.

Key Points: 
  • Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in Berlin, October 11-14, 2023.
  • For more than 40 years, Galderma has focused exclusively on delivering advances in dermatology, and its extensive presence at this year’s congress underlines the true impact of its industry-leading expertise and ongoing commitment to cutting-edge science, brands and services.
  • “We’re so excited to share such an extensive range of new data at EADV this year, and for another opportunity to engage with the community of physicians attending.
  • Results from the phase IV START study reinforce Galderma’s confidence in the efficacy and safety of trifarotene vs. vehicle treatment at reducing atrophic acne scarring.

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

Retrieved on: 
Tuesday, September 26, 2023

HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Key Points: 
  • HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.
  • The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimab in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023

HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment completed; topline data by YE 2023 -
    HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • In July 2023, Celldex announced that enrollment to the CSU study had been completed.
  • CSU EAACI 2023 Data Summary:
    At EAACI 2023 , data were presented on the complete 24 week experience for all patients.
  • In May 2023, Celldex announced that the first patient had been dosed in the Phase 1 study of CDX-585.